BioLife Solutions, Inc. (NASDAQ:BLFS) Given Average Recommendation of “Moderate Buy” by Analysts

BioLife Solutions, Inc. (NASDAQ:BLFS) has earned an average rating of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $31.00.

Several brokerages have recently weighed in on BLFS. Wall Street Zen cut BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Sunday, November 30th. Zacks Research lowered BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 8th. UBS Group reiterated a “buy” rating on shares of BioLife Solutions in a report on Monday. HC Wainwright reissued a “buy” rating and set a $32.00 target price on shares of BioLife Solutions in a research note on Monday, December 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a research note on Wednesday, October 8th.

BioLife Solutions Stock Down 1.2%

Shares of NASDAQ:BLFS opened at $23.89 on Friday. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -341.24 and a beta of 1.93. BioLife Solutions has a twelve month low of $19.10 and a twelve month high of $29.62. The stock’s 50 day moving average is $25.64 and its 200-day moving average is $24.70.

Insider Activity

In other BioLife Solutions news, CFO Troy Wichterman sold 30,000 shares of the stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $25.72, for a total transaction of $771,600.00. Following the completion of the transaction, the chief financial officer owned 152,769 shares of the company’s stock, valued at $3,929,218.68. This represents a 16.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Greef Roderick De sold 37,795 shares of the stock in a transaction on Wednesday, October 22nd. The shares were sold at an average price of $27.30, for a total transaction of $1,031,803.50. Following the transaction, the chief executive officer owned 489,998 shares of the company’s stock, valued at $13,376,945.40. This trade represents a 7.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 937,664 shares of company stock valued at $26,311,309 over the last three months. Corporate insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Tudor Investment Corp ET AL increased its holdings in BioLife Solutions by 85.2% during the third quarter. Tudor Investment Corp ET AL now owns 111,356 shares of the medical equipment provider’s stock valued at $2,841,000 after buying an additional 51,217 shares during the period. Connors Investor Services Inc. bought a new position in shares of BioLife Solutions in the 3rd quarter worth $224,000. CIBC Bancorp USA Inc. bought a new position in shares of BioLife Solutions in the 3rd quarter worth $1,064,000. PharVision Advisers LLC purchased a new stake in shares of BioLife Solutions during the 3rd quarter worth $316,000. Finally, Quarry LP boosted its position in BioLife Solutions by 50.9% during the third quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock valued at $54,000 after purchasing an additional 713 shares in the last quarter. 93.24% of the stock is owned by hedge funds and other institutional investors.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.